News

The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified

The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve

The Phase III program will assess the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled

Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and also as a source of essential fatty acids when a deficiency

MigraPure, which is packaged in pre-measured UnitDose sachets, is a doctor-recommended homeopathic formulation of feverfew and ginger that offers highly effective relief of migraine pain and associated symptoms.

Currently, AG-221 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies. Agios chief medical officer Chris Bowden said the company believes this

RP101 is a proprietary, first-in-class, heat shock protein 27 (Hsp27) inhibitor, administered orally, which may prevent the induction of resistance to chemotherapy (chemoresistance), thus maintaining sensitivity of the

The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK"). In the hope of moving clinical development forward the parties

These options represent an additional $4.1 million to BioCryst in order to advance the development of BCX4430 as a treatment for hemorrhagic fever viruses. NIAID, part of the